Cipla Posts 50% YoY Growth in Profit After Tax in Q3 FY25 Results

Cipla Limited announced its unaudited consolidated financial results for the quarter ended December 31, 2024.

Post the announcement, on January 29, 2025, Cipla share price opened at ₹1,440.00, up from its previous close of ₹1,420.60. At 9:51 AM, the share price of Cipla was trading at ₹1,417.50, down by 0.22% on the NSE.

Q3 FY 2025 Financial Highlights

The Q3 FY25 results marked a milestone with the highest-ever quarterly revenue exceeding ₹7,000 crore and an EBITDA margin surpassing 28%.

The income from operations for the quarter came in at ₹7,073 crore, marking an 8% YoY growth.

Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) for the quarter stood at ₹1,989 crore, reflecting a 28.1% margin and a 16% year-on-year (YoY) growth.

Profit After Tax (PAT) for Q3 reached ₹1,571 crore, with a 22.2% margin and a 50% YoY growth.

Key Updates of the Quarter

The “One-India” business achieved a 10% YoY growth, with the Branded Prescription segment outperforming market growth, Trade Generics returning to a growth trajectory, and CHL’s anchor brands expanding significantly.

In North America, the company delivered quarterly revenue of $226 million, driven by traction in differentiated assets, which offset the Lanreotide supply shortfall. The “One Africa” business maintained its growth momentum with a 9% YoY increase in USD terms, with the Prescription segment securing the #1 market position. Meanwhile, Emerging Markets and Europe posted a strong 20% revenue growth in USD terms.

R&D investments stood at ₹360 crore (5.1% of sales), focused on product filings and development. The company has a net cash position of ₹8,947 crore, primarily covering lease liabilities and working capital needs.

Commenting on the performance, the MD and Global CEO of Cipla Ltd, Umang Vohra, said, “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with the highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY.”

He further added, “Key therapies in the Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained its leadership position. With positive traction in our differentiated assets, the US business posted a revenue of $ 226 Mn. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered substantial revenue growth of 20% YoY on the back of a deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.